SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline

SCYNEXIS ( (SCYX) ) has shared an announcement.

On March 30, 2026, SCYNEXIS entered an asset purchase agreement to acquire Poxel SA’s direct AMP kinase activator program, including the clinical-stage compound PXL-770, now renamed SCY-770, and all related intellectual property, regulatory filings and contracts. The company agreed to pay $8 million upfront and up to $188 million in development and commercial milestones, and also received an exclusive, worldwide, perpetual license to further develop and commercialize the AMPK activator assets.

SCY-770 is a novel, highly selective, oral AMPK activator being developed as a disease-modifying therapy for ADPKD, a rare genetic kidney disorder that is the leading inherited cause of end-stage renal failure and currently has only one approved therapy with safety and tolerability limitations. SCYNEXIS plans to initiate a Phase 2 proof-of-concept trial in ADPKD in the fourth quarter of 2026, with an early efficacy readout expected in the second half of 2027, positioning the acquisition as a transformative expansion of its rare disease pipeline that could diversify its portfolio beyond antifungals and increase its exposure to a sizable orphan nephrology market.

The most recent analyst rating on (SCYX) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.

Spark’s Take on SCYX Stock

According to Spark, TipRanks’ AI Analyst, SCYX is a Neutral.

The score is held back primarily by inconsistent and currently loss-making financial performance (negative margins and negative free cash flow). The strengthened, low-leverage balance sheet is the main offsetting positive, while technical indicators are neutral-to-slightly positive and valuation is constrained by negative earnings and no dividend support.

To see Spark’s full report on SCYX stock, click here.

More about SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company focused on developing innovative therapies for severe and rare diseases, with a pipeline that includes the antifungal platform “fungerps” and the orphan-designated kidney drug candidate SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company has licensed its approved antifungal BREXAFEMME to GSK and is advancing its second-generation antifungal SCY-247 through early-stage clinical development.

SCYNEXIS’s market focus spans rare disease nephrology and serious fungal infections, targeting high unmet-need segments with disease‑modifying or first‑in‑class mechanisms. Its business model combines internal R&D with outlicensing partnerships and milestone- and royalty-based revenue, while pursuing non‑dilutive funding to support ongoing development of its antifungal and rare disease assets.

Average Trading Volume: 376,882

Technical Sentiment Signal: Sell

Current Market Cap: $35.27M

See more insights into SCYX stock on TipRanks’ Stock Analysis page.